BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Yale Cancer Center
New Haven, Estados UnidosPublicaciones en colaboración con investigadores/as de Yale Cancer Center (4)
2017
-
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Cancer Medicine, Vol. 6, Núm. 1, pp. 36-44
2014
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Journal of Hematology and Oncology, Vol. 7, Núm. 1
-
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Biomarker Research, Vol. 2, Núm. 1
2012
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636